News & Events about Rubius Therapeutics Inc.
Alltrna Appoints Caroline Khrer, Ph.D., Vice President, Discovery Platform Alltrna Appoints Caroline Khrer, Ph.D., Vice President, Discovery Platform PR Newswire CAMBRIDGE, Mass., Oct. 17, 2022 Dr. Khrer has more than 25 years of RNA research and development experience, including pioneering novel...
Thinking about buying stock in Rubius Therapeutics, NextPlat, Seres Therapeutics, Cassava Sciences, or Alaunos Therapeutics? Thinking about buying stock in Rubius Therapeutics, NextPlat, Seres Therapeutics, Cassava Sciences, or Alaunos Therapeutics? PR Newswire NEW YORK, Sept. 23, 2022 NEW YORK...
Globe Newswire
4 months ago
CAMBRIDGE, Mass., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a biopharmaceutical company that is developing an entirely new class of cellular medicines called Red Cell Therapeutics for the treatment of cancer and autoimmune diseases, today announced that Pablo J. ...
Thinking about buying stock in Mullen Automotive, American Virtual Cloud Technologies, IVERIC Bio, Rubius Therapeutics, or Globalstar? Thinking about buying stock in Mullen Automotive, American Virtual Cloud Technologies, IVERIC Bio, Rubius Therapeutics, or Globalstar? PR Newswire NEW YORK, Sept...
Rubius Therapeutics's (NASDAQ:RUBY) short percent of float has risen 27.45% since its last report. The company recently reported that it has 3.52 million shares sold short, which is 10.54% of all regular shares that are available for trading.
read more...